GILD - Gilead Sciences, Inc.
| Previous Close | 66.92 |
| Open | 66.63 |
| Bid | 66.88 x 1200 |
| Ask | 66.92 x 1800 |
| Day's Range | 66.30 - 67.26 |
| 52 Week Range | 60.32 - 79.61 |
| Volume | 2,079,179 |
| Avg. Volume | 6,557,151 |
| Market Cap | 85.147B |
| Beta (3Y Monthly) | 1.15 |
| PE Ratio (TTM) | 14.78 |
| EPS (TTM) | 4.53 |
| Earnings Date | Jul 30, 2019 |
| Forward Dividend & Yield | 2.52 (3.70%) |
| Ex-Dividend Date | 2019-06-13 |
| 1y Target Est | 80.19 |
- American City Business Journals•2 hours ago
Cambridge startup Kronos raises $105M in one of the biggest Series A rounds of the year
Kronos Bio CEO Norbert Bischofberger and board member Arie Belldegrun contributed to the Series A round, which is one of the largest in the industry this year.
- Business Wire•5 hours ago
Gilead to Present New Data on HIV Prevention, Treatment and Cure Research at IAS 2019
Gilead Sciences, Inc. today announced that new data from the company’s HIV research and development programs will be presented at the 10th International AIDS Society Conference on HIV Science being held in Mexico City from July 21-24.
- Zacks•20 hours ago
Gilead Sciences (GILD) Stock Moves -0.03%: What You Should Know
Gilead Sciences (GILD) closed at $66.92 in the latest trading session, marking a -0.03% move from the prior day.
- American City Business Journals•yesterday
Top Gilead execs leaving as new CEO continues remake of drug maker
Three executives, in addition to the earlier-announced departure of CFO Robin Washington, will leave Gilead over the next few months.
- Zacks•yesterday
Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
Key highlights of the past week include collaborations and other pipeline updates.
- MarketWatch•yesterday
Gilead's Chief Scientific Officer to leave next month
Gilead Sciences Inc's Chief Scientific Officer John McHutchison will leave the company next month, the company announced Wednesday. McHutchison, who is also Gilead's head of research and development, joined the pharmaceutical giant in 2010 and was named chief scientific officer in March 2018. During his time at Gilead, he oversaw the development of several hepatitis B and C treatments, as well as the company's expansion into oncology with the development of Zydelig. Gilead also announced other changes to its senior leadership team: Chief Patient Officer Greg Alton and Executive Vice President of Human Resources Katie Watson will be leaving, as well. Jyoti Mehra, currently vice president of human resources, will take Watson's place. Shares of Gilead fell 0.4% in premarket trade on the news. The stock has gained 7% in the year to date through Tuesday, while the S&P 500 has gained 19.8%.
- Business Wire•yesterday
Gilead Sciences Announces Changes to Senior Leadership Team
Gilead Sciences, Inc. (GILD) announced today changes to the company’s senior leadership team. Gregg Alton, Chief Patient Officer, and Katie Watson, Executive Vice President, Human Resources, will be departing Gilead. Jyoti Mehra has been named Executive Vice President, Human Resources, and will assume responsibility for the worldwide HR function.
- Business Wire•yesterday
Gilead Sciences’ Chief Scientific Officer John McHutchison to Leave the Company
Gilead Sciences, Inc. (GILD) announced today that John McHutchison, AO, MD, Chief Scientific Officer and Head of Research & Development, has decided to leave the company, effective next month. Dr. McHutchison joined Gilead in 2010 and under his leadership, Gilead has developed five medicines that have been used by more than 3.2 million people around the world for the curative treatment of chronic hepatitis C, and treatment of chronic hepatitis B. He also oversaw the company’s expansion into oncology with the development of Gilead’s first cancer medicine, Zydelig® (idelalisib). During his tenure, he has been responsible for broadening and overseeing the company’s Research and Development pipeline, advancing candidates in new therapeutic areas, including oncology, cell therapy and inflammation.
- Motley Fool•yesterday
Gilead's Galapagos Deal: What It Means for Investors
Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.
- Business Wire•2 days ago
Gilead Sciences to Release Second Quarter 2019 Financial Results on Tuesday, July 30, 2019
Gilead Sciences, Inc. (GILD) announced today that its second quarter 2019 financial results will be released on Tuesday, July 30, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2019 and provide a business update. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 8696029 to access the call.
- Bloomberg•2 days ago
Doctor Who Sold $12 Billion Drug Firm Eyes Biotech Property
(Bloomberg) -- A deal-making cancer doctor who sold his pharmaceutical company for almost $12 billion is launching a real estate venture to bolster the growth of the biotechnology industry.Arie Belldegrun’s family office, Bellco Capital, has entered into a joint venture with New York-based real estate developer Tishman Speyer to start Breakthrough Properties, the companies said Tuesday in a statement. The venture said it bought its first property, a 1-acre (0.4 hectare) development site in Boston’s Seaport District, for $80 million, and is exploring other acquisitions in the area as well as in San Francisco.“This came out of necessity,” Belldegrun said in a telephone interview. “I realized that there’s a significant need for an ecosystem in life sciences where scientists can work and interact.”Belldegrun, 69, is a UCLA-based cancer researcher and surgeon who’s emerged as a serial entrepreneur and venture capitalist. He sold Kite Pharma, which develops genetically engineered cancer treatments, in 2017 to Gilead Sciences Inc. for $11.9 billion and since then has helped launch Vida Ventures to start more pharma companies.Boston SiteBreakthrough Properties will provide various business development services to help tenants grow, Belldegrun said. Vida Ventures, his venture capital arm, may also take stakes in the biotech firms. The Seaport District site comes with 250,000 square feet (23,200 square meters) of development rights and is expected to be finished by 2021, according to the statement.Breakthrough’s chief executive officer is Belldegrun’s son Dan, who worked for Tishman Speyer for several years. Belldegrun’s wife, Rebecka, who is also a doctor, manages Bellco Capital, the family office formed in 2003.The venture -- a foray into life-sciences development for Tishman Speyer -- will face competition from companies such as Alexandria Real Estate Equities Inc., which built its business around catering to biotech tenants. About a quarter of Alexandria’s 250 properties are in the Boston area, while the remainder are spread across U.S. cities including San Francisco, New York and San Diego.Breakthrough has its sights set on some of those cities and ultimately has plans to expand globally, according to Tishman Speyer CEO Rob Speyer.“The last thing a life-sciences company should be worrying about is real estate, and we can take that concern off the table for them,” Speyer said in an interview. “We’re going to focus on strategic cities that have biotech companies, leading universities and quality housing options.”Tishman Speyer, whose properties include New York’s Rockefeller Center, last year sold a 13-story building in Boston’s burgeoning Seaport District for $450 million, setting a record for an office transaction in the city.(Adds potential for competition with Alexandria in seventh paragraph.)To contact the reporters on this story: Michael McDonald in Boston at mmcdonald10@bloomberg.net;Lily Katz in New York at lkatz31@bloomberg.netTo contact the editors responsible for this story: Alan Mirabella at amirabella@bloomberg.net, Josh Friedman, Christine MaurusFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Zacks•2 days ago
Company News for Jul 16, 2019
Companies In The News Are: SYMC,AVGO,GLPG,GILD,BA,AAL,UNIT
- Business Wire•2 days ago
Kite Announces Plans to Bolster Industry-Leading Cell Therapy Manufacturing Capabilities With New Viral Vector Facility
Kite, a Gilead Company , today announced plans for a new 67,000-square-foot facility in Oceanside, California, dedicated to the development and manufacturing of viral vectors, a critical starting material in the production of cell therapies.
- Motley Fool•2 days ago
3 Soaring Biotech Stocks With More Fuel in the Tank
Despite already massive gains this year, shares of these drugmakers could keep on climbing.
- Moody's•3 days ago
Gilead Sciences, Inc. -- Moody's: Gilead's collaboration with Galapagos credit positive
Moody's Investors Service commented that Gilead Sciences, Inc.'s new research and development collaboration with Galapagos NV is credit positive for Gilead. There are no changes to Gilead's A3 existing senior unsecured rating or stable rating outlook. For additional information please refer to Moody's issuer comment on Gilead available on www.moodys.com.
- GuruFocus.com•3 days ago
Wall Street Mixed on Monday
Galapagos skyrockets to an all-time high Continue reading...
- Motley Fool•3 days ago
What Happened in the Stock Market Today
From failed takeover talks to a massive new partnership, see why these stocks were on the move on a quiet day for the broader markets.
- InvestorPlace•3 days ago
Nasdaq Today: Bitcoin & Libra; What’s Broadcom Doing?
There will be a bundle of earnings reports that start to roll out this week. On Monday morning we had a few, but it's about to get busy in the second half of July. Given how much is set to come out over the next few weeks, it was a relatively quiet day on Wall Street Monday. We saw an 0.17% gain in the Nasdaq today, followed by slight gains for the S&P 500 and Dow Jones.Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsThat said, there's a lot individual news to dig through. Bitcoin, Libra and CryptoThe bitcoin market has been wildly volatile lately, hasn't it? Bitcoin prices ran from $5,500 at the start of May to more than $8,700 by June 1st. Just a few weeks later it was north of $13,000. It topped out around $13,600, before it promptly fell to just under $10,000. Crypto bulls said it was an opportunity. Bears argued it was a blowoff top and it was coming back down. Another run to $13,000 earlier this month was again met with sellers as bitcoin prices dropped back down to $10,000. * 7 Dependable Dividend Stocks to Buy I'll stop the onslaught of price history, but it's sort of necessary for an asset like bitcoin. Put simply, this thing is volatile. Perhaps we're entering a range-bound trade, between $10,000 and $13,000. At the very least, traders now have a few lines in the sand, where a move above resistance or below support could spell a further move in that direction. The advances in bitcoin have helped give a boost to Facebook (NASDAQ:FB) stock, even as it's drawn the ire of regulators for its Libra cryptocurrency. Congress has asked Facebook to hold off on Libra until it knows more. It's drawn comments from the president, while U.S. Treasury Secretary Steven Mnuchin said the Treasury has serious concerns over Libra.For its part, Facebook -- which will reportedly settle with the FTC for $5 billion -- said it will wait until it has regulatory support before launching. Heard at the Nasdaq TodayShares of Gilead Sciences (NASDAQ:GILD) were on the move Monday, rising 2.7% and closing at $68.07. It will invest $5.1 billion in Galapagos (NASDAQ:GLPG), increasing its stake in the company from 12.2% to 22%. Galapagos will now see if shareholders approve an eventual stake increase to 29.9%. Given today's action, it's hard to see shareholders saying no, with GLPG stock rising more than 17% to new highs. Further, Gilead Sciences stock was upgraded to outperform at Wells Fargo. The analysts assigned an $88 price target, implying about 30% upside from current levels and signaling new 52-week highs should GILD stock get there. OK, so what's going on with Broadcom (NASDAQ:AVGO) and Symantec (NASDAQ:SYMC)? Broadcom was reportedly in talks to acquire SYMC. However, on Monday, shares of Symantec abruptly tumbled lower, falling over 10% on news that AVGO is no longer in talks to buy the company. However, the stock recovered off its initial lows -- and actually closed at session highs -- while AVGO stock rallied almost 3% on the news, before ending higher by just 1%. New reports say that Broadcom isn't walking away from the deal just yet. So what gives? This is just typical M&A drama. I don't know if Broadcom will pull the trigger for SYMC. Maybe the latter wanted even more money. Perhaps the terms weren't right. Either way, the market seems happy for AVGO to walk away, if that should be a sign of anything. Broadcom stock has been under pressure since the buyout news surfaced and rallied when it looked like the deal was off. Movers in the Nasdaq Today Click to EnlargeAlphabet's (NASDAQ:GOOGL, NASDAQ:GOOG) Google, as well as several social media sites have fallen under criticism that they display a political bias. Google's vice president of government affairs Karan Bhatia wrote an op-ed stating that the company does not have a bias and stated he will tell U.S. Senators that is the case as well. Social media is playing an enormous role in the distribution of political news, both real and fake. It's created a frenzy of both misinformation and information overload, drawing criticism from both political parties. No matter which side of the aisle readers stand on, they should be reading factually correct information, although tech companies haven't seemed to find a very good way to govern it thus far. Tesla (NASDAQ:TSLA) stock is hitting its highest levels since May, rising 3.4% on Monday on above-average volume. The stock is now running into prior support though, which acted as resistance a few months ago. The stock has to reclaim this area to really get the bullish train moving. Amazon's (NASDAQ:AMZN) much-awaited Prime Day is finally here, with sales going strong on Monday and Tuesday. The e-commerce retailer will pull in billions in revenue from the event and is drawing in competition from seemingly every online retailer (seriously, have you checked your inbox lately?) * 5 EV Stocks to Buy for Big Gains Over the Next Decade Target (NYSE:TGT), Costco (NASDAQ:COST), Home Depot (NYSE:HD) -- three strong retailers by the way -- have been hitting it hard, as has Walmart (NYSE:WMT), Best Buy (NYSE:BBY) and others. With a strong labor market, I would expect Amazon's Prime Day numbers to be solid this year. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long AVGO, GOOGL and AMZN. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential The post Nasdaq Today: Bitcoin & Libra; Whatas Broadcom Doing? appeared first on InvestorPlace.
- Investor's Business Daily•3 days ago
Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?
Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.
- Investor's Business Daily•3 days ago
Gilead Pens $5 Billion Research Deal — Why Analysts Still Want A Merger
Galapagos stock rocketed to an all-time high Monday on a deeper $5.05 billion research and development deal with giant biotech company Gilead Sciences. Gilead stock also gained on the news.
- InvestorPlace•3 days ago
Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake
A Galapagos deal with Gilead has GLPG stock heading higher on Monday.Source: Shutterstock As part of a larger deal with Galapagos (NASDAQ:GLPG), Gilead (NASDAQ:GILD) will be purchasing a stake in the company. This will have it acquiring new shares of GLPG stock for €140.59 each. This represents a 20% premium over the stock's 30-day, volume-weighted average price.The Galapagos deal will have Gilead increasing its stake in the company by a fair amount. This will have its ownership of GLPG stock increasing from 12.3% to 22%. Galapagos is also seeking approval from shareholders to allow for two warrants to Gilead. This will let it increase its stake in the company to 29.9%.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis Galapagos deal doesn't just stop with an investment from Gilead. It will also have the two companies working together. This includes a $3.95 billion payment from Gilead that will allow the company to work more on its research and development programs.The Galapagos deal will make it so that Gilead gains exclusive access to the results of research. That will include "exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe." * 7 Dependable Dividend Stocks to Buy There's also the option for additional payments if things go well for Galapagos. For example, Gilead is willing to pay an additional $325 million to the company if GLPG1690 gets approval in the U.S. It will also have the ability to pay a $250 million fee to license the compound for use in the U.S.GLPG stock was up 17% and GILD was up 2% as of Monday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dependable Dividend Stocks to Buy * 10 Stocks Driving the Market to All-Time Highs (And Why) * 7 Short Squeeze Stocks With Big Upside Potential As of this writing, William White did not hold a position in any of the aforementioned securities.The post Galapagos Deal: GLPG Stock Rockets Higher on Gilead Stake appeared first on InvestorPlace.
- Market Realist•3 days ago
Gilead Sciences Expands Collaboration with Galapagos
On July 14, Gilead Sciences announced that it will expand its collaboration with Galapagos (GLPG).
- TheStreet.com•3 days ago
Will Gilead Sciences Stock Really Rally 33% From Here?
Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.
- Bloomberg•3 days ago
Gilead Risks Regrets on Pricey Galapagos Partnership
(Bloomberg Opinion) -- Gilead Sciences Inc.’s new CEO Daniel O'Day is trying to replicate the successful playbook of his former employer Roche Holding AG, the Swiss pharma giant he worked at for more than 30 years. On Sunday, Gilead announced that it would invest $5.1 billion to deepen an existing relationship with Belgian biotechnology firm Galapagos NV. O'Day isn't just committing to Galapagos – he’s committing to the idea of research partnerships that stop short of outright M&A. The deal includes a 10-year standstill agreement that restricts Gilead's ability to acquire the company. O'Day thinks that leaving Galapagos independent will keep it innovative, a bet that paid off for Roche and its productive long-term partnerships with Genentech and Chugai Pharmaceutical Co. That nebulous benefit will have to come through in a big way to justify the price and structure of this deal. Gilead is paying $3.4 billion upfront to gain rights to six drugs in clinical trials and access to a suite of earlier-stage programs. It is also making a $1.1 billion equity investment in Galapagos.The total outlay is a scant $2 billion less than the market cap of Galapagos before the deal was announced, and is above what the company was worth as recently as March. On top of that, Gilead already owned 12 percent of Galapagos and rights to potential blockbuster arthritis drug filgotinib from a $725 million deal completed in 2015. O'Day also isn't done paying up. He will have to shell out more cash to opt in to future programs and for development costs. Gilead will also pay a significant sales royalty if any drugs are approved. And Galapagos will retain European rights for most of its medicines. The potential return of this deal is lower than an outright acquisition, and Gilead didn't seem to get much of a discount. It’s giving up a lot to limit its risk and test the abstract notion that partnerships are superior. The company's late-stage pipeline is sparse, and it is too reliant on its HIV franchise. It’s not in a position to leave upside on the table. There’s a chance that the deal could work out. Gilead’s only has to pay $150 million to gain exposure to programs that are currently in early stages; that could wind up being a relative steal at some point in the next decade. Investors may feel a twinge with every opt-in and royalty check, however. Gilead had chances during the past few years to acquire Galapagos at a lower price than what it’s paying for the partnership now. That feels like a missed opportunity, and may seem even more so if its pipeline and R&D platform turn out to be as strong as O’Day seems to think they are.To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
- Benzinga•3 days ago
Galapagos Notches $3.95B Upfront Investment From Gilead
Gilead said it will make a $3.95-billion upfront payment and $1.1-billion equity investment in the Belgian pharmaceutical company, according to a Sunday press release. Galapagos intends to use the proceeds to expand its research and development programs. As part of a 10-year global research and development collaboration; Gilead will have access to a portfolio of compounds, including six molecules in clinical trials, more than 20 preclinical programs and a drug discovery platform. Galapagos shares were trading higher by 16.34% at $169.56 at the time of publication.
